Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

Completed

Conditions studied: Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma, Effect of Drugs, Safety Issues

In brief

To provide comprehensive efficacy and safety profiles of neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) versus surgery alone in resectable oesophageal carcinoma.

Key facts

Study ID

NCT04027543

Run by

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

People needed

423

Starts

2018-11-14

Expected to finish

2019-12-01

Last updated by the study team

2020-05-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically documented untreated SCC or adenocarcinoma of the oesophagus or gastro-oesophageal junction.
• Patients clinically staged as stage I-III (T1-3, N0-1 and M0) as assessed by a contrast-enhanced multislice computed tomography (CT) scan, positron emission tomography, or endoscopic ultrasonography.
• Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

You may not qualify if…

• Patients had received any previous treatment for oesophageal cancer.
• Patients who were unsuitable for surgery because of comorbidities.
• Patients had evidence of distant metastatic disease by history and physical examination.

Where it is running

• Massachusetts General Hospital of Harvard Medical School — Boston, Massachusetts, United States
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China
• Sun Yat-Sen Memorial Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.